HK1081437A1 - Use of mycobacterial antigen mpb64 in the manufacture of a product for topical detection of active tuberculosis - Google Patents

Use of mycobacterial antigen mpb64 in the manufacture of a product for topical detection of active tuberculosis

Info

Publication number
HK1081437A1
HK1081437A1 HK06101586.2A HK06101586A HK1081437A1 HK 1081437 A1 HK1081437 A1 HK 1081437A1 HK 06101586 A HK06101586 A HK 06101586A HK 1081437 A1 HK1081437 A1 HK 1081437A1
Authority
HK
Hong Kong
Prior art keywords
detection
topical
manufacture
product
active tuberculosis
Prior art date
Application number
HK06101586.2A
Other languages
English (en)
Inventor
Reiko M Nakamura
Original Assignee
Japan Bcg Lab
Reiko M Nakamura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Bcg Lab, Reiko M Nakamura filed Critical Japan Bcg Lab
Publication of HK1081437A1 publication Critical patent/HK1081437A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
HK06101586.2A 1998-02-06 2006-02-07 Use of mycobacterial antigen mpb64 in the manufacture of a product for topical detection of active tuberculosis HK1081437A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7391198P 1998-02-06 1998-02-06
US9614098P 1998-08-11 1998-08-11

Publications (1)

Publication Number Publication Date
HK1081437A1 true HK1081437A1 (en) 2006-05-19

Family

ID=26755032

Family Applications (2)

Application Number Title Priority Date Filing Date
HK01105791A HK1035141A1 (en) 1998-02-06 2001-08-17 Methods and compositions for detection and diagnosis of infectious diseases.
HK06101586.2A HK1081437A1 (en) 1998-02-06 2006-02-07 Use of mycobacterial antigen mpb64 in the manufacture of a product for topical detection of active tuberculosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK01105791A HK1035141A1 (en) 1998-02-06 2001-08-17 Methods and compositions for detection and diagnosis of infectious diseases.

Country Status (10)

Country Link
US (3) US6979450B2 (xx)
EP (1) EP1061905B1 (xx)
JP (1) JP4323600B2 (xx)
CN (3) CN101804213A (xx)
AT (1) ATE306911T1 (xx)
AU (1) AU4480899A (xx)
CA (1) CA2319571C (xx)
DE (1) DE69927794T2 (xx)
HK (2) HK1035141A1 (xx)
WO (1) WO1999039693A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69927794T2 (de) * 1998-02-06 2006-07-13 Japan Bcg Laboratory Zusammensetzungen zum nachweis und zur diagnose von infektiösen mykobakteriellen krankheiten
DE60329676D1 (de) * 2002-05-21 2009-11-26 Arkray Inc Kterien und verfahren zur durchführung einer genamplifikation oder eines gennachweises damit
WO2007130846A2 (en) * 2006-05-03 2007-11-15 Pritest, Inc. Improved compositions and methods of testing for tuberculosis and mycobacterium infection
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
US20120015939A1 (en) * 2010-07-19 2012-01-19 Arcion Therapeutics, Inc. Topical treatment of neuropathic pain and methods of diagnosis
ES2577011B1 (es) * 2015-01-09 2017-04-21 José Antonio FIZ FERNÁNDEZ Procedimiento para la lectura de la reacción de la tuberculina por toma de imágenes térmicas por infrarrojos
KR102192651B1 (ko) * 2017-08-23 2020-12-17 노을 주식회사 시약을 저장하는 저장 매체 및 이를 이용한 검사 방법 및 검사 모듈

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777130A (en) * 1984-12-05 1988-10-11 Andra Biologicals Isolation of mycobacterial a 60 antigen for diagnostic purposes
EP0199362A3 (en) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System and apparatus for delayed and pulsed release of biologically active substances
JP2797308B2 (ja) 1988-03-25 1998-09-17 味の素株式会社 微生物セルロースの産生方法
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
JPH06169758A (ja) 1990-10-09 1994-06-21 Cosmo Sogo Kenkyusho:Kk 微生物及び５−アミノレブリン酸の製造方法
EP0612526A4 (en) * 1991-11-15 1995-08-02 Ss Pharmaceutical Co ANTI-INFLAMMATORY AND ANALGESIC PLATTER.
DK79793D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut Diagnostic test
US5783214A (en) * 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
AU6260796A (en) * 1995-06-07 1996-12-30 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof
JP3624389B2 (ja) 1996-01-30 2005-03-02 日本ビーシージー製造株式会社 Ｂｃｇ菌培養後の使用済み培養液より蛋白質を単離する方法
DE69927794T2 (de) * 1998-02-06 2006-07-13 Japan Bcg Laboratory Zusammensetzungen zum nachweis und zur diagnose von infektiösen mykobakteriellen krankheiten

Also Published As

Publication number Publication date
US20010043905A1 (en) 2001-11-22
CN1679928A (zh) 2005-10-12
CA2319571A1 (en) 1999-08-12
EP1061905B1 (en) 2005-10-19
JP4323600B2 (ja) 2009-09-02
WO1999039693A3 (en) 1999-09-23
WO1999039693A2 (en) 1999-08-12
CA2319571C (en) 2007-09-11
CN1292688A (zh) 2001-04-25
US6979450B2 (en) 2005-12-27
EP1061905A2 (en) 2000-12-27
US20100278742A1 (en) 2010-11-04
CN100584378C (zh) 2010-01-27
CN1194670C (zh) 2005-03-30
DE69927794T2 (de) 2006-07-13
CN101804213A (zh) 2010-08-18
JPH11263736A (ja) 1999-09-28
ATE306911T1 (de) 2005-11-15
US20050106107A1 (en) 2005-05-19
DE69927794D1 (de) 2006-03-02
US7655218B2 (en) 2010-02-02
HK1035141A1 (en) 2001-11-16
AU4480899A (en) 1999-08-23

Similar Documents

Publication Publication Date Title
Dietrich et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity
HK1081437A1 (en) Use of mycobacterial antigen mpb64 in the manufacture of a product for topical detection of active tuberculosis
Dannenberg Jr Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis
BR0009166A (pt) Vacina
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
HUP9900902A2 (hu) Vegyületek és eljárások a tuberkulózis diagnosztikájához és immunterápiájára
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
DK1139755T3 (da) Fremgangsmåde til behandling af baterieinfektioner med rifalazil administreret én eller to gange om ugen
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
PT807178E (pt) Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose
WO2003063899A3 (en) Vaccine adjuvant based on a cd4 0 ligand
EP1914299A3 (en) Identification of virulence associated regions RD1 and RD5 enabling the development of improved vaccines of M. bovis BCG and M. microti
WO2002034773A3 (en) Streptococcal genes
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
WO2000067788A3 (en) Use of soluble costimulatory molecules to enhance immune responses
TR200001948T2 (tr) Mikobakteri vaccaesinden türetilen kompozisyonlar ve bunların kullanımları için metotlar.
NZ511445A (en) Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
DE69510858D1 (de) Mukosale Verabreichung von Pneumokokken-Antigenen
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
EP0836480A4 (en) COMPOSITIONS THAT PROVIDE ADP-RIBOSYL TRANSFERASE ACTIVITY AND METHODS FOR THEIR PRODUCTION AND USE
WO1996039113A3 (en) Oral administration of pneumococcal antigens
WO1998032862A3 (de) L-alanin dehydrogenase von mycobacterium marinum
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections
Chain B. Bloom That is less than clear. We have done virtually no otherantigens. B. Askonas I do remember that you used to havesuppression to Con A responses.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140204